Liraglutide not checked

Biolingus

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
2 active
3 in total · 2 in the EU
Targets
 

What this is

How it works
Copies GLP-1, a gut hormone released after meals that lowers appetite and blood sugar. Same family as Ozempic and Wegovy.GLP-1 Receptor Agonist FDA class
Tested for
Diabete Type 2
Main trialPhase 1/2
“This is a phase Ib/IIa, single ascending dose study of the safety, tolerability and preliminary efficacy of sublingual (SL) Liraglutide in patients with type 2 diabetes mellitus (T2DM).”In the company’s words, NCT05268237 on ClinicalTrials.gov

Other drugs for Diabete Type 2

All 128 drugs for Diabete Type 2

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Dec 2025 Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
Phase 4Ended not given The effect of liraglutide on MMC activity, gastrointestinal hormones, hunger ratings and ad libitum food intake in healthy volunteers.
Phase 4Authorised not given Do GLP-1 based therapies improve the immunological response to vaccination in diabetes?
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Liraglutide

Following is part of Solo: you see every change to Liraglutide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in